New Dosing Trial for Pancreatic Cancer Therapy VCN-01 Launches in Spain
Theriva Biologics begins a Phase 2a trial testing more frequent dosing of its oncolytic virus VCN-01 combined with chemotherapy for metastatic pancreatic cancer.
Summary
Theriva Biologics has received approval from Spanish regulators to begin a small Phase 2a trial testing whether giving its oncolytic virus therapy VCN-01 more frequently can improve outcomes for patients with newly diagnosed metastatic pancreatic cancer. The trial, called VIRAGE2, will enroll six patients at a single Spanish site and combine VCN-01 with standard chemotherapy drugs gemcitabine and nab-paclitaxel. The new schedule delivers at least three treatment cycles spaced two months apart, compared to the two cycles used in the earlier Phase 2b study. Researchers will track safety and how long the virus remains detectable in the blood. The findings are intended to guide dosing decisions for a future larger Phase 3 trial, potentially bringing this therapy closer to wider clinical use.
Detailed Summary
Pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with metastatic disease carrying a median survival often under a year on standard chemotherapy alone. Any therapy that can meaningfully extend survival or improve response rates in this setting represents a significant advance in oncology and, by extension, in the broader fight to extend healthy human lifespan.
Theriva Biologics has received regulatory clearance from Spain's AEMPS to launch VIRAGE2, a Phase 2a proof-of-concept trial evaluating an intensified dosing schedule of VCN-01 — an oncolytic adenovirus engineered to selectively replicate in and destroy tumor cells — combined with gemcitabine and nab-paclitaxel chemotherapy. The trial will enroll six evaluable patients at a single Spanish center.
The key innovation here is frequency: rather than two doses spaced three months apart as in the earlier Phase 2b VIRAGE trial, VIRAGE2 will administer at least three macrocycles of VCN-01 spaced two months apart. Within each macrocycle, VCN-01 is given on day one, followed by chemotherapy across subsequent weeks. The primary endpoints focus on safety — specifically the adverse event profile — and viral genome levels in the bloodstream, which serve as a pharmacodynamic marker of viral activity.
The earlier VIRAGE Phase 2b trial produced encouraging signals: two doses of VCN-01 were associated with improved survival measures, findings notable enough to receive formal recognition from both the EMA and FDA. VIRAGE2 is designed to determine whether more frequent dosing can further amplify those benefits without unacceptable toxicity.
Caveats are important: this is a very small, uncontrolled, single-arm study not powered to detect efficacy differences. It is exploratory by design. With 142 patients treated with VCN-01 to date across all studies, the overall evidence base is still maturing. Nonetheless, for those tracking cancer therapeutics as part of the longevity landscape, this trial represents a meaningful step toward a potential pivotal Phase 3 study.
Key Findings
- VIRAGE2 tests three VCN-01 doses two months apart, increasing frequency versus the prior two-dose Phase 2b schedule.
- Earlier Phase 2b data showed improved survival with VCN-01 plus chemotherapy, recognized by both EMA and FDA.
- Primary endpoints are safety profile and viral genome blood levels, not efficacy — trial is exploratory.
- Only six patients will be enrolled; results will directly inform dosing for a potential Phase 3 pivotal trial.
- VCN-01 has now been administered to 142 patients across all trials to date.
Methodology
This is a news report summarizing a corporate regulatory announcement from Theriva Biologics. The source, Longevity.Technology, is a credible health and longevity news outlet. Evidence basis is a company press release; primary trial data are not yet available.
Study Limitations
The trial enrolls only six patients and is not powered for efficacy, making it unsuitable for drawing conclusions about survival benefit. All current claims of improved survival derive from the earlier Phase 2b study, which has not yet been fully peer-reviewed in detail here. Independent verification of EMA and FDA recognition statements from primary regulatory sources is advisable.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: